Literature DB >> 10462244

Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

J MacLennan1, S Obaro, J Deeks, D Williams, L Pais, G Carlone, R Moxon, B Greenwood.   

Abstract

Forty-two Gambian children randomised to receive two doses of meningococcal A/C polysaccharide vaccine (MPS) in infancy and either MPS (n = 15), meningococcal A/C conjugate (n = 13) or inactivated polio vaccine (IPV n = 14) at 2 years, were revaccinated with MPS at 5 years of age along with 39 matched control children. Meningococcal A and C polysaccharide antibodies were analysed by ELISA and bactericidal assay (SBA) in sera taken before and 10 days after revaccination. The geometric mean group SBA titre in the MPS group following revaccination was about half that of the unvaccinated controls (0.51 95%CI: 0.28, 0.90) for group A and less than half that of the controls for group C (0.41, 95%CI: 0.16, 1.03 P = 0.06). The group C SBA response in the conjugate group was 14-fold higher than in the MPS group (P < 0.001). Multiple doses of meningococcal polysaccharide in childhood may therefore attenuate the SBA response to both group A and group C polysaccharides. In contrast, vaccination with meningococcal A/C conjugate after MPS in infancy gives immunological memory to N. meningitidis group C.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462244     DOI: 10.1016/s0264-410x(99)00139-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

2.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 3.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

4.  Extra-immunization as a clinical indicator for fragmentation of care.

Authors:  Paul M Darden; Kristina K Gustafson; Paul J Nietert; Robert M Jacobson
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

5.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

6.  Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.

Authors:  Q Zhang; R Lakshman; R Burkinshaw; S Choo; J Everard; S Akhtar; A Finn
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  Priming for immunologic memory in adults by meningococcal group C conjugate vaccination.

Authors:  David M Vu; Alberdina W de Boer; Lisa Danzig; George Santos; Bridget Canty; Betty M Flores; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2006-06

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 10.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.